Tumor-targeted agonistic CD28 antigen binding molecules
US11608376B2 · kind B2 · utility
2Cited by
30References
49Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 19, 2019 |
| Grant date | Mar 21, 2023 |
| Priority date | — |
| Expiry date | Dec 19, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.